Global Cancer Vaccine Market ,Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029

Global Cancer Vaccine Market, Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029 Report Highlights:

Global Cancer Vaccine Market Opportunity : > USD 20 Billion By 2029
Cancer Vaccine Market Regional Trends Insight: 10 Countries
Cancer Vaccine Market Trends Insight By Indication: 10 Indications
Insight On Cancer Vaccine In Clinical Trials: > 400 Vaccines
Insight On Cancer Vaccine Commercially available in Market: > 15 Vaccines
Cancer Vaccines Clinical Trials By Company, Country, Indication & Phase
Approved Cancer Vaccines Price & Dosage Analysis
Proprietary Vaccine Manufacturing Technologies By Indication

In the era of modern medicine, innovative advancements are revolutionizing the field of cancer treatment. Among these innovative approaches are cancer vaccines which are emerging as a potential strategy that is offering transformation in the treatment of cancer. Harnessing the power of immune system, these vaccines hold the promise of preventing, treating and ever eliminating various types of cancers. With the development of preventive as well as therapeutic cancer vaccines, it can be predicted that soon, cancer vaccines will hold a major share in the global cancer treatment market.

One of the most significant characteristics about cancer vaccines is their ability to provide personalized and precision medicine. Cancer vaccines can be customized to target specific antigens, mutations or signalling pathways present in a patient’s tumor. By leveraging advancements in genomics and immunology, these vaccines offer a precise and targeted approach, maximizing treatment efficacy while minimizing adverse side effects.

To further enhance treatment outcomes, pharmaceutical companies have been investigating cancer vaccines in combination with other therapeutic modalities. By incorporating vaccines with immune checkpoint inhibitors, targeted therapies or chemotherapy, synergistic effects can be achieved, leading to improved response rates and long term remission. These combination approaches have demonstrated promising results in clinical trials, offering new possibilities for more effective and comprehensive cancer treatment regimes.

Furthermore, the development of cancer vaccines has been fueled by collaboration among pharmaceutical companies, research institutions and healthcare professionals. This collective effort has led to significant advancements in vaccine technology, formulation, optimization and clinical trial design and assessment. Additionally, with the support of government regulatory bodies and global health organizations, cancer vaccines have been progressing rapidly through the development of a robust clinical pipeline.

While cancer vaccines have shown promise in certain cancer types, the future holds a tremendous potential for expanding their application to a wider range of malignancies. Ongoing research is focused on developing vaccines for various solid tumors such as lung cancer, breast cancer, and ovarian cancer among several others. With each breakthrough, the spectrum of cancers that can be effectively treated or prevented with vaccines continues to expand.

As the field of cancer vaccines advances, efforts to ensure global access and collaboration will be a dominant factor. With ongoing research and development, the number of cancer vaccine candidates is increasing, targeting different types of cancers and utilizing various vaccine formulations. The period of COVID-19 determined the importance of vaccines and how effective they can be in controlling disease progression. If same robust research continues towards cancer vaccine development, it can be predicted that not only preventive vaccines but also therapeutic vaccines will enter the global market.

In 2010, Dendreon launched Provenge, making history as it became the first ever therapeutic cancer vaccine. This cell based immunotherapy was targeted towards the treatment of prostate cancer. Achieving this milestone, the entry of Provenge encouraged the growth of other therapeutic cancer vaccines in clinical development. However, therapeutic vaccines have made great advancements in recent years and the products currently in clinical trials represent an era of low toxic treatment options while also addressing several unmet needs that continue in cancer.

Therapeutic cancer vaccines are poised to revolutionize cancer treatment by leveraging the power of immune system against cancer cells. As personalized, targeted therapies, they offer the potential for long lasting responses and improved patient outcomes. By combining these vaccines with other treatment modalities and expanding their reach to a broader range of cancers, researchers are currently paving the way for future where therapeutic cancer vaccines play a pivotal role in cancer treatment. With ongoing research and development, these vaccines will continue to expand the global cancer vaccine market.

Our report provides an in depth analysis about the current research and development landscape of cancer vaccines. Moreover, the report also provides pricing and dosage information about the currently approved preventive and therapeutic cancer vaccines. Apart from this, a regional analysis containing detailed overview about the countries and the intensity with which they are developing cancer vaccines. In addition, the report also provides information about the current market opportunities and the possible future prospects that might open in the global market of cancer vaccines.

1. Introduction To Cancer Vaccines

2. Mechanism Of Cancer Vaccines

2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Global Cancer Vaccine Market Overview

3.1 Current Market Scenario
3.2 Future Market Opportunity

4. Global Cancer Vaccine Market Trends By Country

4.1 US
4.2 Europe
4.3 China
4.4 Japan
4.5 India
4.6 South Korea
4.7 Australia
4.8 South America
4.9 Canada
4.10 UK

5. Cancer Vaccine Market Insight & Proprietary Vaccine Manufacturing Technologies By Indication

5.1 Lung Cancer
5.1.1 Current Clinical Market Trends
5.1.2 Proprietary Manufacturing Technology Platforms
5.2 Pancreatic Cancer
5.2.1 Current Clinical Market Trends
5.2.2 Proprietary Manufacturing Technology Platforms
5.3 Prostate Cancer
5.3.1 Current Clinical Market Trends
5.3.2 Proprietary Manufacturing Technology Platforms
5.4 Bladder Cancer
5.4.1 Current Clinical Market Trends
5.4.2 Proprietary Manufacturing Technology Platforms
5.5 Melanoma
5.5.1 Current Clinical Market Trends
5.5.2 Proprietary Manufacturing Technology Platforms
5.6 Breast Cancer
5.6.1 Current Clinical Market Trends
5.6.2 Proprietary Manufacturing Technology Platforms
5.7 Colorectal Cancer
5.7.1 Current Clinical Market Trends
5.7.2 Proprietary Manufacturing Technology Platforms
5.8 Glioblastoma
5.8.1 Current Clinical Market Trends
5.8.2 Proprietary Manufacturing Technology Platforms
5.9 Ovarian Cancer
5.9.1 Current Clinical Market Trends
5.9.2 Proprietary Manufacturing Technology Platforms
5.10 Human papillomavirus Associated Cancer
5.10.1 Current Clinical Market Trends

6. Approved Cancer Vaccines - Price & Dosage Analysis

6.1 Gardasil/ Gardasil 9
6.2 Cervarix
6.3 Heplisav-B
6.4 PreHevbrio
6.5 Engerix-B
6.6 Twinrix
6.7 Recombivax HB
6.8 Provenge
6.9 Cecolin
6.10 CimaVax
6.11 Vaxira
6.12 Riavax
6.13 Oncophage
6.14 Mycidac-C
6.15 Reniale
6.16 Cervavac*

7. Global Cancer Vaccines Clinical Trials Overview

7.1 By Company
7.2 By Country
7.3 By Indication
7.4 By Patient Segment/Disease Stage
7.5 By Phase

8. Global Cancer Vaccines Clinical Trials By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Registered

9. Marketed Cancer Vaccines Clinical Insight By Company, Country &Indication

10. Competitve Landscape

10.1 Ayala Pharmaceuticals
10.2 BioNTech
10.3 CureVac
10.4 Elicio Therapeutics
10.5 Enochian BioSciences
10.6 Enterome
10.7 EpiThany
10.8 Gradalis
10.9 Hookipa Pharma
10.10 Immunitor
10.11 Immunomic Therapeutics
10.12 In3Bio
10.13 IO Biotech
10.14 ISA Pharmaceuticals
10.15 Jiangsu Recbio Technology
10.16 Mary Crowley Cancer Research Center
10.17 Mayo Clinic
10.18 Memorial Sloan-Kettering Cancer Center
10.19 Mendus
10.20 Merck
10.21 MGFB Bio
10.22 Nykode Therapeutics
10.23 OncoTherapy Science
10.24 pHion Therapeutics
10.25 Qu Biologics
10.26 Scancell
10.27 UbiVac
10.28 Vaccitech
10.29 VAXIMM
10.30 Zhongsheng Kangyuan Biotechnology

List of Figures

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Global - Cancer Vaccine Market Opportunity (US$ Billion), 2023-2029
Figure 3-2: Countries Leading In Clinical Trials for Cancer Vaccines
Figure 4-1: US - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 4-2: Europe - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 4-3: China - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 4-4: Japan - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 4-5: India - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 4-6: South Korea - Cancer Cases & Deaths, 2020
Figure 4-7: South Korea - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 4-8: Australia - Cancer Cases & Deaths, 2020
Figure 4-9: Australia - Pricing for Non-Scheduled NIP HBV & HPV Vaccines (US$), 2023
Figure 4-10: Australia - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 4-11: Canada - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 4-12: CERVARIX - Canada Patents Numbers Approval & Expiration Dates
Figure 4-13: GARDASIL-9 - Canada Patents Numbers Approval & Expiration Dates
Figure 4-14: UK - Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 5-1: Global - Lung Cancer Incidence & Deaths, 2020
Figure 5-2: Global - Lung Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 5-3: Elicio Therapeutics - AMP Platform
Figure 5-4: Global - Pancreatic Cancer Incidence & Deaths, 2020
Figure 5-5: Global - Pancreatic Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 5-6: Global - Prostate Cancer Incidence Among Other cancers, 2020
Figure 5-7: Global - Prostate Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 5-8: The UV1 Vaccine Technology
Figure 5-9: Oxford Vacmedix - Recombinant Overlapping Peptides
Figure 5-10: General Scheme of Process Development & TAPCells Treatment
Figure 5-11: Global - Bladder Cancer Incidence & Death, 2020
Figure 5-12: Global - Bladder Cancer Vaccine Market Opportunity (US$ Million), 2023-2029
Figure 5-13: Lerapolturev - Mechanism of Action
Figure 5-14: Lerapolturev - Activation of APCs & Stimulating Anti Cancer Response
Figure 5-15: T-Win Vaccines - Mechanism of Action
Figure 5-16: Global - Melanoma Incidence & Death, 2020
Figure 5-17: Global - Melanoma Cancer Vaccine Market Opportunity (US$ Million), 2025 - 2029
Figure 5-18: PIONEER - Designing Personalized Cancer Immunotherapy Vaccines
Figure 5-19: Seviprotimut-L - Mechanism of Action
Figure 5-20: Global - Breast Cancer Incidence & Death, 2020
Figure 5-21: Global - Breast Cancer Vaccine Market Opportunity (US$ Million), 2024 - 2029
Figure 5-22: VLP Technology Platform
Figure 5-23: Global - Colorectal Cancer Incidence & Death, 2020
Figure 5-24: Global - Colorectal Cancer Vaccine Market Opportunity (US$ Million), 2025 - 2029
Figure 5-25: BioNTech - iNeST Platform
Figure 5-26: Global - Brain Cancer Incidence & Deaths, 2020
Figure 5-27: Global - Glioblastoma Vaccine Market Opportunity (US$ Million), 2025 - 2029
Figure 5-28: Imvax - Goldspire Platform
Figure 5-29: Goldspire Platform - Antigen Signature Preparation
Figure 5-30: Goldspire Platform - Immune System Training
Figure 5-31: Enterome - OncoMimics Technology Platform
Figure 5-32: UNITE - Mode of Action
Figure 5-33: VBI Vaccines - eVLP Benefits & Structure
Figure 5-34: Global - Ovarian Cancer Incidence & Death, 2020
Figure 5-35: Global - Ovarian Cancer Vaccine Market Opportunity (US$ Million), 2025 - 2029
Figure 5-36: Vididencel - Mode of Action
Figure 5-37: Global - Cancer Caused By High-Risk HPVs
Figure 5-38: Global - HPV Associated Cancer Incidence & Deaths, 2020
Figure 5-39: Global - HPV Vaccine Market Opportunity (US$ Billion), 2023-2029
Figure 6-1: Gardasil - Approval Year by Region
Figure 6-2: Gardasil 9 - Approval Year by Region
Figure 6-3: US - Gardasil Approval Year by Indication
Figure 6-4: Canada - Gardasil Approval Year by Indication
Figure 6-5: Gardasil 9 - Patent Expiration Year by Region
Figure 6-6: US - Cost of 5ml & Per Unit Cost of Gardasil 9 Intramuscular Suspension (US$), May’2023
Figure 6-7: UK - Per Unit Cost of Gardasil & Gardasil 9 Injection (GBP/US$), May’2023
Figure 6-8: Global - Gardasil/ Gardasil 9 Sales Value (US$ Million), 2019-2023
Figure 6-9: Global - Gardasil/ Gardasil 9 Quarterly Sales Value (US$ Million), 2022
Figure 6-10: Cervarix - Approval Year by Region
Figure 6-11: South Korea - Per Unit Cost of Cervarix Injection (KRW/US$), July’2022
Figure 6-12: Global - Cervarix Sales Value (US$ Million), 2019-2023
Figure 6-13: Global - Cervarix Quarterly Sales Value (US$ Million), 2022
Figure 6-14: Regional - Cervarix Annual Sales Value (US$ Million), 2022
Figure 6-15: Regional - Cervarix Annual Sales Value (%), 2022
Figure 6-16: Regional - Cervarix Quarterly Sales Value (US$ Million), 2022
Figure 6-17: Heplisav-B - Approval Years by Region
Figure 6-18: US - Cost of 2.5ml & Per Unit Cost of Heplisav-B Intramuscular Suspension (US$), May’2023
Figure 6-19: Global - Heplisav-B Sales Value (US$ Million), 2019-2023
Figure 6-20: Global - Heplisav-B Quarterly Sales Value (US$ Million), 2022
Figure 6-21: PreHevbrio - Approval Years by Region
Figure 6-22: US - Cost of 10 Vials & Per Unit Cost of PreHevbrio Intramuscular Suspension (US$), May’2023
Figure 6-23: PreHevbrio - Cost of One Cycle & Full Treatment (US$), May’2023
Figure 6-24: US - Cost of 10 Vials & Per Unit Cost of Engerix-B Intramuscular Suspension (US$), May’2023
Figure 6-25: Twinrix - Approval Years by Region
Figure 6-26: US - Cost of 10 Vials & Per Unit Cost of Twinrix Intramuscular Suspension (US$), May’2023
Figure 6-27: Twinrix - Cost of Standard & Accelerated Dosing (US$), May’2023
Figure 6-28: US - Cost of 10 Vials & Per Unit Cost of Recombivax HB Intramuscular Suspension (US$), May’2023
Figure 6-29: US - Cost of 250ml & Per Unit Cost of Provenge Intravenous Suspension (US$), May’2023
Figure 6-30: India - Per Unit Cost of Mycidac-C Injection (INR/US$), May’2022
Figure 7-1: Global - Number of Cancer Vaccines in Clinical Trials by Company, 2023-2029
Figure 7-2: Global - Number of Cancer Vaccines in Clinical Trials by Country, 2023-2029
Figure 7-3: Global - Number of Cancer Vaccines in Clinical Trials by Indication, 2023-2029
Figure 7-4: Global - Number of Cancer Vaccines Clinical Trials by Disease Stage, 2023-2029
Figure 7-5: Global - Number of Cancer Vaccines in Clinical Trials by Phase, 2023-2029

List of Tables

Table 4-1: US - Ongoing Cancer Vaccines Clinical Trials
Table 4-2: EMA - Approved Cancer Vaccines
Table 4-3: Europe - Cancer Vaccines Currently Under Clinical Trial
Table 4-4: China - NMPA Approved Human Papillomavirus Vaccines
Table 4-5: Japan - Merck Held Clinical Trials
Table 4-6: South Korea - Ongoing Cancer Vaccines Clinical Trials
Table 4-7: Australia - TGA Approved Hepatitis-B Vaccines
Table 4-8: Australia - TGA Approved Human Papillomavirus Vaccines
Table 4-9: Australia - Ongoing Melanoma Vaccines Clinical Trials
Table 4-10: South America - Cancer Vaccines Currently Under Clinical Trial
Table 4-11: Canada - Approved Cancer Vaccines
Table 4-12: Canada - Cancer Vaccines Currently Under Clinical Trial
Table 4-13: UK - Approved Cancer Vaccines
Table 4-14: UK - Cancer Vaccines Currently Under Clinical Trial

Samples

LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Ayala Pharmaceuticals
BioNTech
CureVac
Elicio Therapeutics
Enochian BioSciences
Enterome
EpiThany
Gradalis
Hookipa Pharma
Immunitor
Immunomic Therapeutics
In3Bio
IO Biotech
ISA Pharmaceuticals
Jiangsu Recbio Technology
Mary Crowley Cancer Research Center
Mayo Clinic
Memorial Sloan-Kettering Cancer Center
Mendus
Merck
MGFB Bio
Nykode Therapeutics
OncoTherapy Science
pHion Therapeutics
Qu Biologics
Scancell
UbiVac
Vaccitech
VAXIMM
Zhongsheng Kangyuan Biotechnology

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3481EUR$3,600USD£2,984GBP
CD-ROM	The CD-ROM will be shipped to you.		€4642EUR$4,800USD£3,978GBP
Hard Copy	A printed copy of the product will be shipped to you.		€4932EUR$5,100USD£4,227GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5802EUR$6,000USD£4,973GBP